API | siplizumab

siplizumab Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

siplizumab

allomune

More Chemistry

Pharmacology

Mechanisms of Action:
- T-cell surface antigen CD2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

allomune | medi507 | medi-507 | siplizumab

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)

Graft vs Host Disease (Phase 1)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 2)

Kidney Transplantation (Phase 2)

Leukemia (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Lymphoproliferative Disorders (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Psoriasis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue